Introduction
Gastrointestinal stromal tumors (GIST) are rare tumors with an annual incidence of 1.5 new cases every 100 000 inhabitants; nevertheless, they are the most common type of the gastroenteric tract mesenchymal tumors. The majority of GIST (∼85-90%) are associated with gain-offunction KIT gene mutations, which lead to constitutive activation of KIT kinase activity and uncontrolled cell proliferation. A smaller proportion (5%) is associated with analogous mutations in platelet-derived growth factor receptor α and less than 10% contain no identified receptor tyrosine-kinase mutations (wild-type GIST) [1] [2] [3] .
Traditional cytotoxic treatments, which are the standard option in other subtypes of sarcoma, are ineffective in GIST. Elucidating the GIST molecular pathophysiology as a mutation driven process has enabled the development of targeted kinase inhibitor therapies, which have revolutionized treatment strategies and clinical outcomes for patients with advanced GIST [4] .
Imatinib mesylate represents the standard first-line therapy for metastatic GIST patients [5] . It has markedly improved prognosis and outcome, increasing progressionfree survival (PFS) to 18 months and the median overall survival from 19 to 55 months [6, 7] .
After oral consumption of imatinib, bioavailability exceeds 90%. Its metabolism is mostly hepatic and the principal isoenzymes involved are CYP3A4 and CYP3A5 of the cytochrome P450 family. As these enzymes are also involved in the metabolism of several other common substances, interactions leading to amplification or weakening of the action of those drugs are frequent in the case of coadministration [8, 9] .
In advanced GIST patients who are intolerant or resistant to imatinib, sunitinib malate is the standard second-line treatment [10] , whereas regorafenib is the latest inhibitor introduced in the GIST treatment strategy [11] .
The considerable efficacy of imatinib in the metastatic setting led to its use also in neoadjuvant and adjuvant settings. Furthermore, more recently, rechallenge of imatinib after failure of previous treatment with multiple tyrosine-kinase inhibitors (TKIs), including at least imatinib and sunitinib, has become a common strategy adopted in clinical practice [12] [13] [14] [15] [16] . The standard imatinib dosage is 400 mg/day, even if patients with exon 9 mutations showed better PFS with the high daily imatinib administration of 800 mg [7, 17] . Dose escalation could also be adopted as a treatment strategy after progression at 400 mg [18] .
Imatinib is generally well tolerated, although almost every patient had at least some mild or moderate adverse events (AEs) that might have been related to therapy. Common side effects include fluid retention such as periorbital and widespread edema, nausea, diarrhea, fatigue, loss of appetite, skin rash, and myalgia or muscle cramps. The most serious AEs were gastrointestinal or intra-abdominal hemorrhages in patients with large, bulky tumors, which occurred in ∼ 5% of patients [5] . The high daily dosage of imatinib 800 mg has been associated with a high incidence of grades 3, 4, and 5 toxicities compared with the standard dosage [7] .
A continuous and regular daily imatinib consumption is required to obtain better PFS and outcome; therefore, good compliance with treatment is an important goal in clinical practice, but it could be difficult to achieve in the increasing subset of patients with advanced age [19] [20] [21] [22] [23] [24] . Indeed, the physiological and functional characteristics of such patients as well as comorbidities treated with one or more drugs could result in exacerbated adverse effects associated with polypharmacy and drug-drug interactions. Therefore, comorbidity and polypharmacy can significantly influence the success of the treatment [25] .
The aim of this study is to discuss whether the use of personalized imatinib dosage could be a safe and advantageous option, enabling continuous administration, thus ensuring effective treatment, especially for elderly patients.
Whereas numerous studies using alternative doses or schedules of sunitinib have been carried out especially in metastatic renal cell carcinoma patients [26] [27] [28] [29] , only a few case reports in the literature provide data on outcome with low tailored dosage of imatinib and none of them has been carried out on a Western population [30] [31] [32] [33] [34] [35] .
Here, we report four cases treated with low imatinib dosage as a safe and useful option enabling achievement of a positive outcome and clinical benefits.
Materials and methods
Between December 2001 and April 2015, 67 patients with metastatic or advanced GIST were treated at the Ematology and Medical Oncology Unit 'L&A Seràgnoli', S. Orsola-Malpighi Hospital, University of Bologna (Bologna, Italy), with imatinib as first-line therapy. The primary treatment schedule was selected according to KIT mutational status. Patients with the exon 11 KIT mutation were treated with the recommended dose of 400 mg/day, whereas patients with exon 9 KIT mutation were treated with 800 mg/day.
In 63 out of the 67 patients, adverse reactions during imatinib administration were treated with either temporary dose reduction or suspension, standard supporting medical treatments, or switching to second-line treatment with sunitinib. Conversely, in four cases out of 67, treatment with imatinib was prolonged despite intolerance through the adoption of personalized measures.
We will focus on these four patients starting with the description of their clinical history. Their clinical and molecular features are described in Table 1 .
Results

Case 1
In October 2011, an 89-year-old man without significant comorbidities or medical history presented to our hospital with abdominal pain and fever. The contrast-computed tomography (CT) scan showed a mass of 7 cm in the small bowel without other pathological lesions. Because of signs and symptoms of ileus subocclusion, he underwent surgical resection of the mass and the appendix.
The histological exam indicated a high-risk GIST with intense positivity for CD117 and the mutational analysis showed a classical exon 11 KIT mutation.
Considering his age and preference, no adjuvant treatment was administered and a follow-up program was planned.
In December 2012, a CT scan showed five liver metastases, the greater in the II segment, three out of five, hypermetabolic at fluorine-18 fluorodeoxyglucose ( 18 F-FDG)-PET. Considering liver relapse, treatment with the standard dosage of imatinib was started and, 1 month after the administration of the first drug, no hypermetabolic lesions were identified by early 18 F-FDG-PET ( Fig. 1 ).
The following CT scans showed a reduction in the size and/or the density of the known lesions; therefore, according to Choi's criteria [37] , all lesions showed good sensitivity to imatinib. However, during this period, we observed suboptimal tolerance to drug because of fatigue, and periorbital and leg edema.
In March 2014, the onset of pleural effusion and dyspnea led to suspension of imatinib. A cardiologic assessment was performed and a specific diuretic therapy was adopted.
Despite clinical benefit, any attempt at imatinib reintroduction resulted in a rapid worsening of symptoms, causing repeated interruptions, until suspension of treatment in September 2014. The CT scan performed 2 months later showed a marked increase in the size of the liver lesions. Thus, considering both the toxicity and the high efficacy of the previous treatment, we opted for a tailored imatinib administration with prescription of half the recommended dose (200 mg/day). Such personalized dosage led to increased compliance, reduced AEs (only dizziness was reported) and impressive disease response, which was confirmed by all CT scans performed afterwards (for about 12 months, to date) ( Fig. 2 ).
Case 2
In January 2015, an 85-year-old woman underwent an abdominal ultrasound exam for dyspepsia and epigastric pain, and a gastric mass about 55 mm in size was observed, confirmed at CT scan. The echoendoscopic biopsy indicated a diagnosis of GIST.
Considering the site and the absence of metastases, we proposed a surgical approach as the first step, but the patient refused surgery in favor of imatinib-based therapy. Taking into account the patient's age and her other chronic disease, we decided to start with a daily dose of 400 mg/day of imatinib instead of 800 mg/day as recommended by the mutational analysis (exon 9 KIT mutation).
Treatment was started in March 2015: the patient's compliance with treatment was very high and the only AE reported was mild fatigue.
Although suboptimal dosage was administered, early 18 F-FDG-PET compared with the baseline one showed a metabolic activity reduction of the lesion (standardized uptake value = 2.7 vs. 6.0) ( Fig. 3 ) and the last CT scan showed a reduction in the size (45 × 43 mm) and hypodensity of the gastric lesion ( Fig. 4 ).
Case 3
An 81-year-old woman was diagnosed with locally advanced rectal GIST in July 2011.
Because of the onset of abdominal pain and chronic constipation, the patient underwent several examinations. An abdominal CT scan detected a neoplasm about 54 mm in size, arising from the anterior wall of the lower rectum. On MRI examination, an involvement of the left elevator ani muscle and vagina was found. Ultrasoundguided transrectal biopsy diagnosed a CD117 + /CD34 + GIST and the mutational analysis indicated an exon 11 KIT mutation.
A surgical approach was initially excluded, considering the demolitive intervention required with permanent abdominal colostomy; thus, neoadjuvant imatinib therapy at the standard dose of 400 mg per day was started.
The treatment was continued for 6 months, with a very favorable response at early 18 F-FDG-PET ( Fig. 5 ) and at risk of malignancy index evaluation (reduction in the size of the mass of about 23 mm and tumor density, with a prevailing pattern of necrosis, according to the Choi criteria). However, the patient experienced grade 3 spread skin rash and neutropenia that were managed with antihistamine therapy and several temporary dose interruptions. To clarify the causes of this toxicity, possible drug-drug interactions and incorrect drug intake were investigated and excluded; therefore, in January 2012, the medical treatment was discontinued.
A surgical reassessment provided no indication for the intervention again because of the invasiveness of surgery and preferences of the patient; thus, a second-line medical treatment with sunitinib was started at the dosage of 37.5 mg/day continuously. Because of marked weakness, severe mucositis, anorexia, dysgeusia, and tremor, this treatment was also prematurely withdrawn.
Taking into account the old age, the absence of symptoms, the poor tolerance to medical treatment, and the patient's preference, we decided to monitor clinical and instrumental disease evolution through medical examination and risk of malignancy index every 3 or 4 months.
From May 2012 to March 2014, a slight but steady increase in the size of the rectovaginal lesion was observed. In October 2014, the patient reported vaginal spotting, fatigue, and pain in the lower back, and MRI evaluation showed significant disease progression (increase in size of about 35 mm). Having ruled out surgery and considering the previous favorable response to imatinib, we decided on a rechallenge with imatinib at a lower dose of 200 mg/day. The MRI evaluation performed after 4 months of personalized treatment showed a partial response with a reduction in the size and density of the rectal lesion (49 × 36 × 51 vs. 64 × 42 × 65 mm) ( Fig. 6 ). Clinically, symptoms associated with tumor mass, such as bleeding and tenesmus, decreased significantly and both skin and hematologic toxicity profile improved, allowing for continuous treatment, thus implementing a successful balance between efficacy and toxicity and maintaining the patient on treatment to date (13 months).
Case 4
In March 2009, a 70-year-old woman underwent emergency surgical resection of an ileal mass for acute abdomen secondary to perforation during a bioptic procedure. A bleeding, broken mass arising from the small bowel and surrounded by serum-hematic material was found at laparotomy. No other lesions were detected during abdominal cavity exploration.
Histopathology indicated a CD117 + , DOG1 + , highrisk GIST mutated at exon 11 KIT gene. An abdominal CT scan performed 2 months after surgery was negative for synchronous metastases and macroscopical peritoneal residue of disease.
Despite the high risk of developing peritoneal recurrence, no adjuvant treatment was performed because of the slow and difficult clinical recovery during the postoperative course. The patient thus begun an instrumental and clinical follow-up program.
In December 2012, the patient was hospitalized for the onset of abdominal pain and distension and a marked CT scan image after suspension of imatinib (a): the five hepatic lesions in the right and left lobes showed a marked increase in size. The largest one in the II segment measured 55 × 59 mm and showed hypervascular, hyperdense components, especially along the periphery. CT scan image after 5 months of treatment with imatinib (b): the lesion in the II segment decreased in size significantly (37 × 29 mm) and became completely hypodense. CT, computed tomography. A first-line treatment with imatinib at a standard dose of 400 mg daily was started, but was discontinued prematurely after a few weeks because of the onset of fatigue and grade 3 itchy skin rash resistant to antihistamines and topical corticosteroids.
Given the poor tolerance to imatinib, a treatment with sunitinib (37.5 mg/day) was administered, in turn prematurely suspended because of severe toxicity, in particular, oral mucositis, and a follow-up program was planned.
In March 2014, a new intraperitoneal bleeding occurred, which was treated surgically with the removal of a friable and bleeding abdominal metastasis adherent to the hepatic flexure of the colon.
Considering the overall clinical picture and toxicities caused by both previously administered drugs, but also age and low BMI (16.18) of the patient, we decided to propose a personalized schedule with imatinib at a lower dose of 300 mg daily, thus allowing to overcome toxicities and maintain a stable, asymptomatic disease (not detectable at CT scan) to date (19 months).
Discussion
The advent of imatinib mesylate marked a revolutionary clinical step in the treatment of patients with unresectable or advanced GIST. It is an oral selective inhibitor of KIT and platelet-derived growth factor receptor α kinase activities and represents the first-line therapy for metastatic GIST patients; it has markedly improved prognosis and outcomes, providing a meaningful clinical benefit and extending the 2-year survival to more than 70% compared with previous chemotherapy treatments [5] [6] [7] .
Imatinib is generally well tolerated and most AEs can be managed with the careful use of supportive care without dose reduction or interruption of treatment. However, some patients develop more severe AEs, particularly in advanced age, showing a broader spectrum of treatmentrelated toxicities, because of several conditions, that is, predisposition to alterations in drug metabolism and excretion, comorbidities, concurrent medications, and decreased bone marrow reserves.
Currently, the elderly cancer population in Western countries is expanding as a result of both improvements in life expectancy and increasing cancer incidence with age. However, patients older than 65 years of age are underrepresented in cancer clinical trials, whereas they constitute the major proportion of the real cancer population in clinical practice. This is particularly true for early phase studies of dose determination [38, 39] .
Besides these considerations, in the era of tailored cancer medicine, the necessity of more personalized therapies has emerged not only on the basis of molecular targets but also modeled on the individual characteristics of each patient, especially in the geriatric population. Therefore, if dose optimization of the antineoplastic is a major challenge in the general population, it is even more relevant in the elderly because of additional age-related factors and lack of available data on this population in clinical trials [40, 41] . Here, we report four cases of very old and frail patients in whom, despite the occurrence of several adverse effects, imatinib treatment was continued through the adoption of a reduced/halved dosage, mainly to overcome toxicities while maintaining good results in terms of response. The four patients presented different disease conditions, namely, liver metastases (first case), localized gastric GIST (second case), locally advanced, symptomatic, rectal GIST (third case), and peritoneal disease spread (fourth case). Thus, the alternative dosage was tested in different settings.
The decision to continue imatinib at a reduced dose was driven by multiple reasons related to knowledge on imatinib treatment strategies and the individual characteristics and clinical history of each patient. In particular:
(1) Prolonging therapy with the most effective drug for the given mutation. (2) Improving compliance with treatment, thus maintaining steady suppression of KIT/PDGFRA kinase activity. (3) Avoiding initiation of other treatments that, although effective, could worsen the patient's clinical condition and disease symptoms (i.e. bleeding lesions). (4) Avoiding anticipation of a second-line treatment when the first line is still effective, thus maximizing the duration of each therapy line and ultimately the overall sequential treatment strategy.
Notably, in three out of four cases presented, there was a mutation in KIT exon 11. This molecular feature of our patients reinforced our decision to continue imatinib even if at a reduced dose.
In fact, it is established that the kinase genotype is of major prognostic significance for PFS and overall survival in patients treated with imatinib for advanced GIST and correlates with the probability of achieving a response to treatment [42] [43] [44] [45] .
These findings, besides confirming the importance of mutational testing for patients with GIST before starting TKI therapies, highlight the concept that imatinib is the most effective treatment in advanced GIST harboring exon 11 KIT mutations.
All these observations, together with low BMI and old age of our patients, reinforced the decision of dose adjustment to overcome side effects and maximize the effectiveness/toxicity balance of imatinib treatment.
Although evaluation of imatinib blood levels was not carried out in the current population, it can be reasonably assumed that adequate plasma levels of the drug were maintained because of the old age and very low BMI of our patients.
In terms of BMI, dosing chemotherapy on the basis of body surface area is a well-established practice, since individual basal metabolic rates are related to weight. Few data are available on BMI and target therapies, which are administered at a fixed dose irrespective of body surface area. Only recently have some studies focused on this issue: Antoun et al. [46] reported that BMI less than 25 kg/m 2 with decreased muscle mass was a significant predictor of toxicity in 55 metastatic renal cell carcinoma patients treated with sorafenib 400 mg twice daily. Similarly, Telli et al. [47] carried out a study on 48 patients affected by metastatic renal cell carcinoma treated with sunitinb and reported that a lower BMI, together with a history of heart or coronary artery diseases, were factors associated with an increased risk of high-grade cardiotoxicity (grade 3/4), which results in dose reduction or discontinuation of treatment.
In the cases reported here, three out of four patients presented a very low BMI (range BMI: 16.18-20.99) and experienced severe side effects by imatinib at the standard dose. The fourth patient had normal weight, but would require double the dose of imatinib because of a KIT exon 9 mutation.
The 'one dose fits all' approach in the administration of TKIs certainly has its advantages, but does not take into account several important sources of interindividual variations that can arise because of differences in BMI, heterogeneous body composition, and, specifically, the relative amounts of lean and adipose tissue, target protein's expression, drug metabolism, and excretion.
Other factors possibly involved in the response to treatment could be investigated against the genetic background of patients. Several studies have shown that genetic polymorphisms in drug metabolizers and transporters might cause large variability in imatinib plasma concentration, affecting imatinib efficacy and toxicity, especially in chronic myeloid leukemia. In particular, the human multidrug resistance gene (MDR1, ABCB1) single nucleotide polymorphisms (MDR1 1236, 2677, and 3435 single nucleotide polymorphisms) have proven to be significantly different between resistant and sensitive patients [48] . In another recent study, using a panel of 31 polymorphisms in 11 genes potentially associated with the pharmacogenetics of imatinib, the polymorphisms SLC22A4 and SLC22A5 in imatinib transporters genes were identified as predictors of response to imatinib: specifically, they improved time to progression in GIST patients receiving imatinib therapy [49] .
Unquestionably, the mechanisms that lead to secondary resistance or unusual excessive toxicity to imatinib are still largely unclear; further studies on genotyping and other factors that influence drug exposure are required to optimize individualized GIST treatment and represent an important attractive opportunity for new clinical trials.
It may be interesting to further explore the reduced dosage option also in the setting of pretreated patients, for example in case of imatinib rechallenge. Resumption of imatinib is commonly performed with the goal of delaying disease progression and palliating symptoms for patients with GIST after the failure of all approved TKIs [50] [51] [52] . Moreover, the RIGHT study reported a statistically significant improvement in PFS from 0.9 to 1.8 months in favor of the reintroduction of imatinib compared with placebo after progression on treatment with at least imatinib and sunitinib [16] . The beneficial effects of rechallenge therapy with imatinib are possibly attributable to a continuous kinase inhibition by this drug in the tumor clones that retain sensitivity to imatinib.
In this setting, because of the increased volume of disease and poor performance status, the patient's compliance with treatment with imatinib is generally reduced; therefore, it may be reasonable to adopt customized schedules, aiming to achieve disease stabilization or decreased progression together with a good toxicity profile.
Interestingly enough, the cases reported in this paper are the only reports of elderly and Western patients treated with personalized imatinib schedules as the few cases described in the literature focused only on Asian patients [30] [31] [32] [33] [34] [35] .
Different aspects in terms of the efficacy, toxicity, and metabolism of TKIs among different ethnic groups are already well known in other tumors, such as lung cancer and renal cancer. The Asian phenotype in never-smoker women with lung adenocarcinoma is more frequently associated with specific somatic mutations of the epidermial growth factor receptor, which presented sensitivity to gefinitinib and erlotinib [53] [54] [55] . Notably, different toxicity profiles have been described on administration of sunitinib in Korean patients with advanced renal cell carcinoma, in particular, in the frequencies of hematological toxicities [56] .
It seems possible that these ethnic differences are associated with a lower metabolic capacity of CYP3A4 and specific isozymes of CYP345 such as CYP3A5.3, which are more frequent in Asian populations [57] [58] [59] [60] .
Conclusion
In conclusion, although imatinib has been in use for about 15 years now, many different applications and possibilities still remain to be explored. Dose customization is one of these, especially for selected subsets of patients or specific genotypes. Once again, imatinib could represent a paradigm for other target drugs and/or other cancer types. We hope that the four real cases reported in this paper will stimulate further research on these topics.
